Schizophrenia, described as the worst disease affecting mankind, is a severe and disabling mental disorder.  Schizophrenia is characterized by complicated symptoms and still lacks a diagnostic neuropathology, so developing schizophrenia animal models which have quantifiable measures tested in a similar fashion in both humans and animals will play a key role in new therapeutic approaches.  According to the symptoms of cognitive impairment and emotional disorder, the N-methyl-d-aspartate (NMDA)-receptor antagonist MK-801 was applied to induce schizophrenia-like behavior in mice.  Locomotor activity and prepulse inhibition (PPI) were selected as indices and the effect of clozapine was also investigated in this model.  The results showed that compared with the normal group, MK-801-treated mice exhibited significantly increased locomotor activity and impaired PPI, and pre-exposure to clozapine could ameliorate the abnormality and make it back to normal level.  These findings suggest that the model we established could be a useful tool for antipsychotic drug screening.